PEGNANO
PEGNANO (Peginterferon alfa – 2a)
Therapeutic indications
Chronic hepatitis B:
Pegnano is indicated for the treatment of HBeAg-positive or HBeAg-negative-chronic hepatitis B in adult patients with compensated liver disease and evidence of viral replication, increased ALT and histologically verified liver inflammation and/or
Chronic hepatitis C:
Pegnano is indicated for the treatment of chronic hepatitis C in adult patients who are positive for serum HCV-RNA, including patients with compensated cirrhosis and/or co-infected with clinically stable HIV.
The optimal way to use Pegnano in patients with chronic hepatitis C is in combination with ribavirin. The combination of Pegnano and ribavirin is indicated in naive patients and patients who have failed previous treatment with interferon alpha (pegylated or non-pegylated) alone or in combination therapy with ribavirin.
Monotherapy is indicated mainly in case of intolerance or contraindication to ribavirin.
